Please Wait
Applying Filters...
menu
    • menu
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    evonik-m-2025-09-08

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Menu

    Paltusotine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    $ API Ref.Price (USD/KG) : 18,356Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Crinetics to Present PALSONIFY Acromegaly Data at ENDO 2025
    Crinetics to Present PALSONIFY Acromegaly Data at ENDO 2025

    13 Jul 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/07/13/3114463/0/en/Crinetics-to-Present-New-Long-Term-Data-Demonstrating-Durable-Control-of-Once-Daily-Oral-PALSONIFY-Paltusotine-in-Acromegaly-at-ENDO-2025.html

    GLOBENEWSWIRE
    13 Jul 2025
    Share Share
    Crinetics to Showcase Endocrinology Innovation at ENDO 2025
    Crinetics to Showcase Endocrinology Innovation at ENDO 2025

    30 Jun 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/06/30/3107872/0/en/Crinetics-to-Showcase-the-Next-Generation-of-Endocrinology-Innovation-at-ENDO-2025-with-Eight-Presentations-From-its-Deep-Pipeline.html

    GLOBENEWSWIRE
    30 Jun 2025
    Share Share
    Crinetics Pharma's MAA, ODD For Paltusotine In Acromegaly Validated
    Crinetics Pharma's MAA, ODD For Paltusotine In Acromegaly Validated

    27 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/03/27/3050988/0/en/Crinetics-Pharmaceuticals-Announces-European-Medicines-Agency-EMA-Validation-of-Marketing-Authorization-Application-MAA-and-Orphan-Drug-Designation-ODD-for-Paltusotine-in-Acromegal.html

    GLOBENEWSWIRE
    27 Mar 2025
    Share Share
    Crinetics Announces FDA Acceptance of Paltusotine for Acromegaly
    Crinetics Announces FDA Acceptance of Paltusotine for Acromegaly

    09 Dec 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/12/09/2993693/0/en/Crinetics-Announces-FDA-Acceptance-of-New-Drug-Application-for-Paltusotine-for-Adult-Patients-with-Acromegaly.html

    GLOBENEWSWIRE
    09 Dec 2024
    Share Share
    Crinetics Submits NDA For Paltusotine For Treatment Of Acromegaly
    Crinetics Submits NDA For Paltusotine For Treatment Of Acromegaly

    26 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/26/2954138/0/en/Crinetics-Submits-New-Drug-Application-for-Paltusotine-for-the-Treatment-of-Acromegaly.html

    GLOBENEWSWIRE
    26 Sep 2024
    Share Share
    Crinetics Positions Paltusotine As Potential Acromegaly First Choice
    Crinetics Positions Paltusotine As Potential Acromegaly First Choice

    03 Jun 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/06/03/2892444/0/en/Crinetics-Presents-New-Data-at-ENDO-2024-that-Increases-Body-of-Evidence-Positioning-Once-Daily-Oral-Paltusotine-as-Potential-First-Choice-Treatment-Option-for-Acromegaly.html

    GLOBENEWSWIRE
    03 Jun 2024
    Share Share